A phase I randomized, double‐blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Translational Science"
DOI: 10.1111/cts.13286
Abstract: Rezafungin is a novel echinocandin being developed for the treatment and prevention of invasive fungal infections. The objectives of this randomized, double‐blind study in healthy adults were to determine the safety, tolerability, and pharmacokinetics of… read more here.
Keywords: safety tolerability; rezafungin; randomized double; double blind ... See more keywords
Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections
Sign Up to like & getrecommendations! Published in 2021 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.00842-21
Abstract: Rezafungin is a novel antifungal agent of the echinocandin class with potent activity against species of Candida and Aspergillus, including subsets of resistant strains, and Pneumocystis jirovecii. The objective of this analysis was to develop… read more here.
Keywords: pharmacokinetics rezafungin; population; population pharmacokinetics; rezafungin ... See more keywords
Pharmacodynamic Evaluation of Rezafungin (CD101) against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model
Sign Up to like & getrecommendations! Published in 2018 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01572-18
Abstract: Rezafungin (CD101) is a novel echinocandin under development for once-weekly intravenous (i.v.) dosing. We evaluated the pharmacodynamics (PD) of rezafungin against 4 Candida auris strains, using the neutropenic mouse invasive candidiasis model. ABSTRACT Rezafungin (CD101)… read more here.
Keywords: invasive candidiasis; rezafungin; mouse invasive; candida auris ... See more keywords